Broad-Spectrum Legionaminic Acid-Specific Antibodies in Pooled Human IgGs Revealed by Glycan Microarrays with Chemoenzymatically Synthesized Nonulosonosides
Open Access
Abstract
The presence and the level of antibodies in human sera against bacterial glycans are indications of prior encounters with similar antigens and/or the bacteria that express them by the immune system. An increasing number of pathogenic bacteria that cause human diseases have been shown to express polysaccharides containing a bacterial nonulosonic acid called 5,7-di-N-acetyllegionaminic acid (Leg5,7Ac2). To investigate the immune recognition of Leg5,7Ac2, which is critical for the fight against bacterial infections, a highly effective chemoenzymatic synthon strategy was applied to construct a library of α2–3/6-linked Leg5,7Ac2-glycans via their diazido-derivatives (Leg5,7diN3-glycans) formed by efficient one-pot three-enzyme (OP3E) synthetic systems from a diazido-derivative of a six-carbon monosaccharide precursor. Glycan microarray studies using this synthetic library of a Leg5,7Ac2-capped collection of diverse underlying glycan carriers and their matched sialoside counterparts revealed specific recognition of Leg5,7Ac2 by human IgG antibodies pooled from thousands of healthy donors (IVIG), suggesting prior human encounters with Leg5,7Ac2-expressing pathogenic bacteria at the population level. These biologically relevant Leg5,7Ac2-glycans and their immune recognition assays are important tools to begin elucidating their biological roles, particularly in the context of infection and host–pathogen interactions.Keywords
Funding Information
- National Institutes of Health (NIH) (R01AI130684, R01GM141324, S10OD025271, ISF-IPMP no. 3042/22, ERC-2020-COG-101003021, DBI-0722538)
- Israel Science Foundation—Israel Precision Medicine Program (R01AI130684, R01GM141324, S10OD025271, ISF-IPMP no. 3042/22, ERC-2020-COG-101003021, DBI-0722538)
- European Research Council Consolidator (R01AI130684, R01GM141324, S10OD025271, ISF-IPMP no. 3042/22, ERC-2020-COG-101003021, DBI-0722538)
- National Science Foundation (R01AI130684, R01GM141324, S10OD025271, ISF-IPMP no. 3042/22, ERC-2020-COG-101003021, DBI-0722538)
This publication has 58 references indexed in Scilit:
- Metabolic Labeling of Legionaminic Acid in Flagellin Glycosylation of Campylobacter jejuni Identifies Maf4 as a Putative Legionaminyl TransferaseAngewandte Chemie International Edition, 2021
- Synthesis of Nonulosonic AcidsEuropean Journal of Organic Chemistry, 2020
- A versatile de novo synthesis of legionaminic acid and 4-epi-legionaminic acid starting from d-serineCarbohydrate Research, 2019
- A Diazido Mannose Analogue as a Chemoenzymatic Synthon for Synthesizing Di‐N‐acetyllegionaminic Acid‐Containing GlycosidesAngewandte Chemie International Edition, 2018
- Total Biosynthesis of Legionaminic Acid, a Bacterial Sialic Acid AnalogueAngewandte Chemie International Edition, 2016
- Preparation of legionaminic acid analogs of sialo-glycoconjugates by means of mammalian sialyltransferasesGlycoconjugate Journal, 2015
- Pasteurella multocida sialic acid aldolase: a promising biocatalystApplied Microbiology and Biotechnology, 2008
- Quantifiable fluorescent glycan microarraysGlycoconjugate Journal, 2007
- Highly Efficient Chemoenzymatic Synthesis of Naturally Occurring and Non‐Natural α‐2,6‐Linked Sialosides: A P. damsela α‐2,6‐Sialyltransferase with Extremely Flexible Donor–Substrate SpecificityAngewandte Chemie International Edition, 2006
- Chemoenzymatic synthesis of CMP–sialic acid derivatives by a one-pot two-enzyme system: comparison of substrate flexibility of three microbial CMP–sialic acid synthetasesBioorganic & Medicinal Chemistry, 2004